Skip to Content

Pharmalive?s New ?Investigational Drug Review And Outlook? Special Report Analyzes Compounds In Development That Show Promise For Unmet Medical Need

NEWTOWN, Pa., April 26, 2010 – Canon Data Products Group and announce the release of a new Special Report, “Investigational Drug Review and Outlook.” This report provides professionals working in or serving the pharmaceutical and biotechnology industries with analysis of the current drug development environment, business and R&D strategies being employed by companies, and expected market impact of the top 100 investigational medicines.

Developing novel and much-needed treatments for rare diseases is the primary focus for many small, specialized pharmaceutical and biotechnology companies. Many large cap pharmaceutical companies recognize the potential of these prospective medicines and have partnered with their counterparts, licensed intellectual property, or implemented M&A strategies to bolster their pipelines and offset the impact of the looming patent cliff.

There are several compounds in development in Phases I through III that have demonstrated significant promise and could significantly improve upon current regimens, thus improving patient quality of life. Additionally, these potential treatments could have a significant impact on market share for currently marketed brands.

“Orphan medicines are becoming a larger source of concentration for some drug developers, particularly biologics,” says Andrew Humphreys, editor in chief of Canon Data Products Group. “Helping the cause, the U.S. government continues to explore ways to reduce the costs of developing orphan products and provide financial incentives for companies to bring to market such medications. The healthcare industry needs more orphan drugs on the market such as Benlysta, which during 2010 could be the first new medicine approved for lupus in more than five decades.”

The compounds included in this report were selected because they demonstrate particular promise in a major or growing therapeutic area of unmet need, are actively in Phase I through Phase III development, and target disease pathways with distinctly innovative mechanisms of action.

Product highlights include anticipated monoclonal antibodies for autoimmune diseases such as lupus and rheumatoid arthritis; emerging treatments for thrombosis and diabetes; and experimental inhibitors for Parkinson’s disease, Alzheimer’s disease, and schizophrenia.

This PharmaLive Special Report is available at

For more information, contact Sandra Baker at 215-944-9836 or

About Canon Data Products Group
Canon Data Products Group, a division of Canon Communications LLC, publishes PharmaLive and Appliance Special Reports, which provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries; maintains eKnowledgeBase, a comprehensive market intelligence tool serving the pharmaceutical, biotechnology, and medical device sectors; and manages company-wide Site Licenses for, Med Ad News, and R&D Directions.



Sandra Baker


Posted: April 2010